Stay updated on NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Sign up to get notified when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.

Latest updates to the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedFooter metadata changes: added Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe page history shows a site release update: Revision: v3.3.2 added and Revision: v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check36 days agoChange DetectedVersion label updated from v3.2.0 to v3.3.1 in the page footer; no visible changes to study data or primary content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedRemoved the government funding status notice from the page, and core trial history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check58 days agoChange DetectedThe new version updates the study status and the list of contacts/locations compared with the previous version. These changes reflect shifts in recruitment status and site availability.SummaryDifference0.0%

- Check79 days agoChange DetectedPage now shows a newer date and updated study-status entry, replacing an older date; overall meaning shifts toward current status information without affecting core transactional elements.SummaryDifference0.6%

Stay in the know with updates to NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Enter your email address, and we'll notify you when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.